Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
暂无分享，去创建一个
F. Saad | E. Posadas | K. Chi | M. De Meulder | N. Shore | A. Yu | B. Espina | R. Mamidi | J. Lattouf | J. Graff | E. Zhu | A. Hazra | Branislav Bradic | P. Francis | V. Hayreh | A. Rezazadeh Kalebasty | Arash Rezazadeh Kalebasty